Last update 21 Jun 2024

Meropenem

Last update 21 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, Mepem, Meropen

+ [16]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesHemic and Lymphatic Diseases+ [3]

Active Indication

Complicated intra-abdominal infectionCommunity acquired respiratory tract infectionComplicated skin and skin structure infection+ [9]

Inactive Indication

Pneumonia, BacterialPneumonia, Ventilator-Associated

Originator Organization

Sumitomo Pharma Co., Ltd.

Active Organization

Pfizer Australia Pty Ltd.

B. Braun Medical, Inc.

Amneal Intermediate, Inc.

+ [4]

Inactive Organization

Melinta Therapeutics, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (04 Sep 1995),

Bacterial InfectionsFebrile Neutropenia

RegulationOrphan Drug (US)

Structure

Molecular FormulaC17H27N3O6S

InChIKeyWCDAAZJSDNCCFU-NACOAMSHSA-N

CAS Registry119478-56-7

156

Clinical Trials associated with Meropenem

NCT06184659 / Not yet recruitingPhase 4IIT

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

Start Date01 Aug 2024

Sponsor / Collaborator-

NCT05784844 / RecruitingPhase 4IIT

Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial

Febrile neutropenia is often seen in patients with hematologic malignancies who receive cytotoxic chemotherapy. These patients are usually placed on posaconazole prophylaxis upon starting chemotherapy. If an episode of febrile neutropenia occurs, generally an anti-pseudomonal beta lactam, like cefepime or piperacillin-tazobactam, is initiated. In patients who continue to fever on these agents, the optimal method of antimicrobial revision has yet to be determined.

Start Date01 Aug 2024

Sponsor / Collaborator

Wake Forest School of Medicine

CTR20233345 / RecruitingPhase 1

注射用FL058在不同程度肾功能不全受试者中的药代动力学研究

[Translation] Pharmacokinetic study of FL058 for injection in subjects with different degrees of renal insufficiency

主要目的:评价单剂静脉滴注FL058、美罗培南与FL058联合（仅重度肾功能不全受试者）在不同程度肾功能不全受试者中的药代动力学（PK）特征。次要目的：评价单剂静脉滴注FL058、美罗培南与FL058联合（仅重度肾功能不全受试者）在不同程度肾功能不全受试者中的安全性和耐受性。

[Translation]

Primary objective: To evaluate the pharmacokinetic (PK) characteristics of a single intravenous infusion of FL058 and the combination of meropenem and FL058 (only subjects with severe renal insufficiency) in subjects with different degrees of renal insufficiency. Secondary objective: To evaluate the safety and tolerability of a single intravenous infusion of FL058 and the combination of meropenem and FL058 (only subjects with severe renal insufficiency) in subjects with different degrees of renal insufficiency.

Start Date27 Dec 2023

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Meropenem

100 Translational Medicine associated with Meropenem

100 Patents (Medical) associated with Meropenem

9,618

Literatures (Medical) associated with Meropenem

31 Dec 2024·Emerging microbes & infections

Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition

Article

Author: Wang, Rui ; Huang, Sijing ; Zhang, Xuyao ; Yang, Yunkai ; He, Peng ; Liu, Xiaofen ; Li, Jiyang ; Yang, Shangye ; Wang, Yue ; Feng, Meiqing ; Qi, Mengya

ABSTRACTNew Delhi metallo-β-lactamase-1 (NDM-1) has rapidly disseminated worldwide, leading to multidrug resistance and worse clinical prognosis. Designing and developing effective NDM-1 inhibitors is a critical and urgent challenge. In this study, we constructed a library of long-lasting nitroxoline derivatives and identified ASN-1733 as a promising dual-functional antibiotic. ASN-1733 can effectively compete for Ca²⁺ on the bacterial surface, causing the detachment of lipopolysaccharides (LPS), thereby compromising the outer membrane integrity and permeability and exhibiting broad-spectrum bactericidal activity. Moreover, ASN-1733 demonstrated wider therapeutic applications than nitroxoline in mouse sepsis, thigh and mild abdominal infections. Furthermore, ASN-1733 can effectively inhibit the hydrolytic capability of NDM-1 and exhibits synergistic killing effects in combination with meropenem against NDM-1 positive bacteria. Mechanistic studies using enzymatic experiments and computer simulations revealed that ASN-1733 can bind to key residues on Loop10 of NDM-1, hindering substrate entry into the enzyme's active site and achieving potent inhibitory activity (K_i= 0.22 µM), even in the presence of excessive Zn²⁺. These findings elucidate the antibacterial mechanism of nitroxoline and its derivatives, expand their potential application in the field of antibacterial agents and provide new insights into the development of novel NDM-1 inhibitors.

01 Mar 2024·The Science of the total environment

Recovery and genetic characterization of clinically-relevant ST2 carbapenem-resistant Acinetobacter baumannii isolates from untreated hospital sewage in Zhejiang Province, China

Article

Author: Zhang, Yanyan ; Wu, Yuchen ; Yan, Zelin ; Zhang, Rong ; Ruan, Zhi ; Ju, Xiaoyang ; Gu, Danxia ; Chen, Kaichao ; Chen, Sheng ; Zhang, Jun ; Chan, Edward Wai Chi ; Xie, Miaomiao

The global transmission of carbapenem-resistant Acinetobacter baumannii (CRAB) poses a significant and grave threat to human health. To investigate the potential relationship between hospital sewage and the transmission of CRAB within healthcare facilities, isolates of Acinetobacter spp. obtained from untreated hospital sewage samples were subjected to antimicrobial susceptibility tests, genome sequencing, and bioinformatic and phylogenetic tree analysis, and that data were matched with those of the clinical isolates. Among the 70 Acinetobacter spp. sewage isolates tested, A. baumannii was the most prevalent and detectable in 5 hospitals, followed by A. nosocomialis and A. gerneri. Worryingly, 57.14 % (40/70) of the isolates were MDR, with 25.71 % (18/70) being resistant to carbapenem. When utilizing the Pasteur scheme, ST2 was the predominant type among these CRAB isolates, with Tn2006 (ΔISAba1-bla_OXA-23-ATPase-yeeB-yeeA-_ΔISAba1) and Tn2009 (_ΔISAba1-bla_OXA-23-ATPase-hp-parA-yeeC-hp-yeeB-_ΔISAba1) being the key mobile genetic elements that encode carbapenem resistance. Seven A. gerneri isolates which harbored Tn2008 (ISAba1-bla_OXA-23 -ATPase) and the bla_PER-1 gene were also identified. Besides, an A. soil isolate was found to exhibit high-level of meropenem resistance (MIC ≥128 mg/L) and harbor a bla_NDM-1 gene located in a core genetic structure of ISAba125-bla_NDM-1-ble-trpF-dsbC-cutA. To investigate the genetic relatedness between isolates recovered from hospital sewage and those collected from ICUs, a phylogenetic tree was constructed for 242 clinical isolates and 9 sewage isolates. The results revealed the presence of two evolutionary clades, each containing isolates from both ICU and sewage water, suggesting that CRAB isolates in untreated sewage water were also the transmission clones or closely related evolutionary isolates recoverable in hospital settings. Findings in this work confirm that hospital sewage is a potential reservoir of CRAB.

01 Mar 2024·American journal of infection control

The impact of the COVID-19 pandemic on gram-negative bacteria susceptibility patterns in respiratory samples of intensive care units in the Brussels Capital Region, 2010-2021

Article

Author: Jonckheer, Joop ; Miendje Deyi, Véronique Y ; De Geyter, Deborah ; Moretti, Marco ; Claus, Marc ; Dauby, Nicolas ; Clevenbergh, Philippe ; Wybo, Ingrid

BACKGROUND:

The effect of the Coronavirus Disease 2019 (COVID-19) pandemic on gram-negative bacteria nonsusceptibility to antibiotics is unclear.

METHODS:

Between January 1, 2010, and December 31, 2021, the respiratory samples of intensive care unit patients at 3 University Hospitals in Brussels were retrieved. Based on the nonsusceptibility to antimicrobial classes, drug-resistance patterns were defined as multi-drug-resistant, extensively drug-resistant, and pan-drug-resistant. The study time frame was divided into 6 periods of 2 years each, and the impact of the COVID-19 pandemic (last period: 2020-2021) was assessed.

RESULTS:

During the current study, 10,577 samples were identified from 5,889 patients. While a significant augmentation of multi-drug-resistant isolates was noticed once comparing 2 prepandemic periods (2012-2013 and 2014-2015), all 3 patterns of nonsusceptibility significantly increased, comparing the years before and throughout the COVID-19 pandemic (2018-2019 and 2020-2021). Globally, the greatest increase in antimicrobial nonsusceptibility, comparing the last 2 periods, was reported for piperacillin-tazobactam (from 28% to 38%). Pseudomonas aeruginosa was the most isolated species, and the most involved in the appearance of resistance, with an augmentation of nonsusceptibility percentage to meropenem of 22% (from 25% to 47%), between the prepandemic and the pandemic periods.

CONCLUSIONS:

The COVID-19 pandemic was associated with increasing trends of antimicrobial resistance in respiratory samples of patients admitted to the intensive care units in university hospitals with well-implemented antibiotic stewardship programs.

News (Medical) associated with Meropenem

06 Jun 2024

·www.biospace.com

MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China

According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activity against multidrug-resistant Gram-negative. Bacteria ("MDR-GNB"), indicating significant clinical application potential. In China, the total number of days of antibiotic treatment for MDR-GNB infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3% during this period. SHANGHAI, June 6, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals. MRX-8 is primarily used to treat infections caused by multidrug-resistant Gram-negative bacteria. This significant milestone marks a crucial step towards MRX-8 becoming a safe and effective new antibacterial drug. China Phase I Clinical Trial Results The Phase I clinical trial in China was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of MRX-8 in healthy Chinese subjects. The trial included single ascending dose and multiple ascending dose components, demonstrating that MRX-8's drug exposure in the human body increases proportionally with the dose. The study demonstrated that at the expected clinical dose of 2.5 mg/kg once daily, MRX-8 can achieve ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria. Moreover, MRX-8 exhibited good safety in healthy Chinese adults. Throughout the study, no subjects withdrew or terminated the trial due to adverse events, and no CTCAE Grade 3 or higher adverse events occurred. The most common adverse events were mild sensory reduction and decreased glomerular filtration rate, all of which were CTCAE Grade 1 and resolved without intervention. Only two subjects in the multiple dose group experienced CTCAE Grade 2 adverse events, both of which were injection site reactions.. The Study's Impact and Future Plans As one of the company's important new drug development product pipelines, the successful completion of the Phase I clinical trial of MRX-8 in China is of great significance. The study results indicate that MRX-8 exhibits good safety in healthy Chinese adults at the expected clinical dose, laying a solid foundation for its future clinical use. The success of this clinical trial not only provides strong data support for subsequent clinical development, but also enhances confidence in its future application in treating multidrug-resistant Gram-negative bacterial infections. This marks a crucial step forward for MRX-8 in becoming a safe and effective new antibacterial drug. The company will combine the results and data from both the US and China Phase I clinical trials to formulate the next steps in MRX-8's clinical development plan. The company will actively explore development pathways for different potential indications, aiming to make MRX-8 a new antibacterial drug with significant clinical value for treating multidrug-resistant Gram-negative bacterial infections, in order to meet the rapidly growing need for clinical treatment. The company is committed to creating maximum value for society and the company, driving MRX-8 towards market availability, and providing new hope for patients. About MRX-8 MRX-8 is a novel injectable polymyxin antibacterial drug independently developed by MicuRx Pharmaceuticals, primarily used to treat severe infections caused by multidrug-resistant Gram-negative bacteria. Traditional polymyxin drugs have limited clinical use due to their high risk of nephrotoxicity and neurotoxicity. MRX-8, through meticulous structural design, not only maintains or improves therapeutic efficacy, but also significantly reduces these toxic risks. Results from the Phase I clinical trial completed in the United States in 2022 showed that MRX-8 achieves ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Multidrug-Resistant Gram-Negative Bacteria and Market Demand Gram-negative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics. Multidrug-resistant Gram-negative bacteria (MDR-GNB) are a specific class of Gram-negative bacteria whose multidrug resistance is defined as resistance to three or more commonly prescribed antibiotics (ceftazidime, ciprofloxacin, meropenem, gentamicin, ampicillin/sulbactam, or piperacillin/tazobactam). Infections caused by MDR-GNB have a mortality rate five times higher than infections caused by conventional Gram-negative bacteria. Globally, infections caused by multidrug-resistant Gram-negative bacteria have become a major public health challenge. According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. In hospitals and intensive care units, infections caused by resistant Gram-negative bacteria result in high mortality rates and significant treatment costs, posing substantial pressure on healthcare systems. In China, the total number of days of antibiotic treatment for MDR-GNB infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3%.[1] Currently, the market has limited options for effectively treating multidrug-resistant Gram-negative bacterial infections, and the severe side effects of traditional polymyxin drugs further restrict their clinical use. The development and clinical trial results of MRX-8 address this unmet market need. MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activity against multidrug-resistant Gram-negative bacteria, indicating significant clinical application potential. [1] Data source: Frost & Sullivan Analysis View original content: SOURCE MicuRx Pharmaceuticals

Phase 1Clinical ResultMicrobial therapy

23 May 2024

·www.biospace.com

Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris

Publication reaffirms the efficacy of rezafungin for treatment of candidemia and invasive candidiasis (IC) in adult patients across Candida species PARSIPPANY, N.J.--(BUSINESS WIRE)-- Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed ReSTORE phase 3 global clinical trial evaluating REZZAYO® (rezafungin for injection) for the treatment of candidemia and invasive candidiasis (IC) in adults. The data analyses in the article, “Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis,” published in the American Society for Microbiology Antimicrobial Agents and Chemotherapy, demonstrates the efficacy of rezafungin in adult patients across a variety of Candida species. Rates of global cure and mycological eradication at day 14 and all-cause mortality at day 30 were generally comparable between the two treatment groups. The article additionally highlights the approval of the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints for rezafungin against several Candida species including Candida glabrata, a species increasingly associated with reduced susceptibility to treatment with echinocandins, and Candida auris, a highly resistant pathogen that is associated with life-threating infections. Rezafungin is the only antifungal, based on in vitro data, that has a defined susceptibility breakpoint for C. auris approved by CLSI; the efficacy of rezafungin in treating candidemia or invasive candidiasis caused by this pathogen has not been established in adequate and well-controlled clinical trials. Christine Ann Miller, president and chief executive officer of Melinta Therapeutics, said, "We are delighted with the release of this analysis of data from the ReSTORE Phase 3 trial, which supports the effectiveness and safety of REZZAYO in comparison to caspofungin and are also pleased to see that CLSI approved the REZZAYO susceptibility breakpoints for Candida pathogens, including C. auris, which has been identified as a potential global threat by the CDC and WHO.” She added, "Melinta has been leveraging our expertise in hospital and acute care environments to commercialize REZZAYO, making it available to healthcare providers and their patients affected by candidemia and invasive candidiasis. This effort supports our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses." Melinta holds the exclusive rights to commercialize rezafungin in the U.S. from Mundipharma. About REZZAYO® (rezafungin for injection) REZZAYO (rezafungin for injection) is a novel once weekly echinocandin approved in the United States for the treatment of candidemia and invasive candidiasis in adults. REZZAYO is currently being studied for the prevention of invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation. INDICATIONS AND USE REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. IMPORTANT SAFETY INFORMATION Contraindications REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. Warnings and Precautions Infusion-related Reactions: REZZAYO may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion. Photosensitivity: REZZAYO may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation. Hepatic Adverse Reactions: Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO therapy. Adverse Reactions Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. Please see the full Prescribing Information for REZZAYO (rezafungin for injection), available at . About Melinta Therapeutics, LLC Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit .

Phase 3Drug ApprovalLicense out/inClinical Result

16 May 2024

·www.biospace.com

Venatorx Pharmaceuticals Announces Changes to Executive Leadership

MALVERN, Pa.--(BUSINESS WIRE)-- Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team. Manos Perros, PhD, has been appointed to the Board of Directors as Executive Chairman. Dr. Perros is a distinguished pharmaceutical and biotech executive with an impressive track record that includes more than 25 years in life sciences research and development. He was previously Chief Executive Officer and co-founder of Entasis Therapeutics, where he successfully positioned the company as a leader in the antimicrobial space, resulting in its acquisition by Innoviva in 2022. While at Entasis, Dr. Perros oversaw the development of Xacduro, which recently earned U.S. Food and Drug Administration approval as the first targeted treatment for Acinetobacter baumannii pneumonia. Prior to founding Entasis, Dr. Perros held the positions of Vice President and Head of AstraZeneca’s Infection Research and Early Development organization and Site Head for AstraZeneca’s Boston R&D research center. Dr. Perros also served as Director of the Novartis Institute for Tropical Diseases in Singapore, and Vice-President and Chief Scientific Officer, Antivirals, at Pfizer, where he led an R&D program that culminated in the approval of Selzentry, a first-in-class treatment for HIV. Dr. Perros’ appointment follows the resignation of Christopher J. Burns, Ph.D., who has stepped down as Chief Executive Officer and Director of Venatorx Pharmaceuticals. Additionally, Tomas J. Heyman has stepped down as Non-Executive Chairman of the Board. “On behalf of the entire Company, I would like to personally thank Chris for his dedication and tireless perseverance to lead Venatorx for over 14 years as an innovative pioneer in the fight against anti-microbial resistance. The Board of Directors sincerely appreciates his contributions along with the endless support and leadership that have guided the Company toward achieving its mission. I am delighted to join Venatorx Pharmaceuticals and to have an opportunity to help advance cefepime-taniborbactam through regulatory review and toward FDA approval to address the growing unmet need for novel treatments for patients suffering from multi-drug resistant gram-negative bacterial infections,” Dr. Perros said. “As recent Phase III data in The New England Journal of Medicine established, cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis, while having a similar safety pro meropenem. This therapy has enormous potential and may represent a significant improvement over the standard of care that could support global health efforts to combat antibiotic-resistant infections for patients around the world.” About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead program, cefepime-taniborbactam, is a clinical-stage antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections. Venatorx is also developing an oral antibacterial, ceftibuten-ledaborbactam (formerly known as VNRX-7145), for the treatment of cUTI, including pyelonephritis, caused by certain bacteria in adult patients with limited treatment options; this product is completing Phase 1 and will advance directly to a global Phase 3 cUTI clinical trial. For more information about Venatorx and its anti-infectives portfolio, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical development of Venatorx Pharmaceuticals’ product candidates.

Phase 3Executive ChangeDrug ApprovalAcquisitionClinical Result

100 Deals associated with Meropenem

External Link

KEGG	Wiki	ATC	Drug Bank
D08185	Meropenem	J01DH02	DB00760

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Complicated intra-abdominal infection	US	B. Braun Medical, Inc.	30 Apr 2015
Community acquired respiratory tract infection	AU	Pfizer Australia Pty Ltd.	25 Jul 1996
Complicated skin and skin structure infection	AU	Pfizer Australia Pty Ltd.	25 Jul 1996
Complicated urinary tract infection	AU	Pfizer Australia Pty Ltd.	25 Jul 1996
Gynecological infection	AU	Pfizer Australia Pty Ltd.	25 Jul 1996
Hospital-acquired pneumonia	AU	Pfizer Australia Pty Ltd.	25 Jul 1996
Meningitis	AU	Pfizer Australia Pty Ltd.	25 Jul 1996
Intraabdominal Infections	US	Pfizer Inc.	21 Jun 1996
Meningitis, Bacterial	US	Pfizer Inc.	21 Jun 1996
Skin and skin structure infections	US	Pfizer Inc.	21 Jun 1996
Bacterial Infections	JP	Sumitomo Pharma Co., Ltd.	04 Sep 1995
Febrile Neutropenia	JP	Sumitomo Pharma Co., Ltd.	04 Sep 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumonia, Bacterial	Phase 3	-	Melinta Therapeutics, Inc.	01 Aug 2018
Pneumonia, Ventilator-Associated	Phase 3	-	Melinta Therapeutics, Inc.	01 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05102162 (CTgov)	Phase 4	Pneumonia	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	cyywyefmpv(rfvdiodfnq) = kvgcplxmde tvihhnptsh (mqwuyxgupv, ksfuqnoqah - hmcrdyycvf) View more	-	12 Dec 2023
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	cyywyefmpv(rfvdiodfnq) = dupzsrnbxp tvihhnptsh (mqwuyxgupv, keheqhhtfm - vlevfqbcbc) View more
FDA Manual	Not Applicable	Meningitis, Bacterial	446	Meropenem 40 mg/kg	pwehjlakjm(dfzdahdbsb) = Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis. kmwjkisppu (gtzvofmevu )	Positive	26 Jul 2023
				cefotaxime or ceftriaxone
NCT03174184 (CTgov)	Phase 2	Pulmonary Tuberculosis	112	MEROPENEM 2 grams TID+Rifampin+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant A)	byudfcmnqi(zzlpvsvatv) = ocfjhohvsk bsnickmqiy (ovahnmjfvd, bsckvbxiem - bgxdrbgivm) View more	-	19 Jul 2023
				MEROPENEM 2 grams TID+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant B)	byudfcmnqi(zzlpvsvatv) = ibjqocvkli bsnickmqiy (ovahnmjfvd, qllfwcgzqq - jkfmcojnwy) View more
NCT03174184 (COMRADE, Pubmed)	Phase 2	Tuberculosis Second line	112	Meropenem 2 grams 8 hourly	iqywzmnfmg(ztdeeouucm) = Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. hekoqvctzg (tezlwpwroi )	Negative	08 Mar 2022
				Meropenem 2 grams 8 hourly plus rifampin 20 mg/kg once daily
NCT01597973 (CTgov)	Phase 3	Sepsis \| Pneumonia	467	placebo	tgthjkoeda(ipelgyhxft) = wizvbdpqzs naxbyyviwu (uwicafhvag, miedpfiswv - ewdhmshopz) View more	-	30 Nov 2021
NCT03019965 (CTgov)	Not Applicable	Sepsis	426	Meropenem+Imipenem+Piperacillin+Tazobactam (Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem)	rbllscvwle(efvmvxieuw) = lehygqqewu pnnlvjanyg (xoapzgodmz, sfcvocvfiv - dpfrulijtw) View more	-	05 Aug 2021
				Meropenem+Imipenem+Piperacillin+Tazobactam (Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem)	rbllscvwle(efvmvxieuw) = jzlosqkmqo pnnlvjanyg (xoapzgodmz, ndnlawkqsl - rjpucndyfp) View more
NCT05578586 (Pubmed \| J Intensive Care Med)	Not Applicable	Critical Illness	-	Extended Infusion Meropenem (EIM)	cokzjxjsjt(cqbizdwqed) = izikxiwjym tivmtydjxf (oeurugezky ) View more	Positive	01 Aug 2020
				Intermittent Infusion Meropenem (IIM)	cokzjxjsjt(cqbizdwqed) = uzdxmfffvu tivmtydjxf (oeurugezky ) View more
Pubmed \| Antimicrob Agents Chemother	Not Applicable	Critical Illness	-	Standard dosage regimens for meropenem	svwherqafw(fobckhbrlv) = xyrcctppjj qceeaqfqnb (oeytovzrqh )	-	22 Jul 2020
NCT01551394 (NeoMero1, Pubmed) Manual	Phase 3	Neonatal Sepsis	272	Meropenem (Meropenem arm)	vuakxruydm(kbqyxbsroq) = qkbqhekway bmrsvetvye (ufnffkcxrx ) View more	Non-superior	04 Mar 2020
				ampicillin+gentamicin+cefotaxime (SOC arm)	vuakxruydm(kbqyxbsroq) = fjocrtazqg bmrsvetvye (ufnffkcxrx ) View more
ASN2019	Not Applicable	Peritoneal dialysis-associated peritonitis	8	Continuous IP Meropenem	dqdkebjzgj(wpcqamcjjt) = caovcnbaoa yxcvwehsag (iabcqcksoy, 36.2)	Positive	05 Nov 2019
				Intermittent IP Meropenem	dqdkebjzgj(wpcqamcjjt) = skupglyltf yxcvwehsag (iabcqcksoy, 35.7)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis